These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 34454548)

  • 1. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.
    Vaisitti T; Arruga F; Vitale N; Lee TT; Ko M; Chadburn A; Braggio E; Di Napoli A; Iannello A; Allan JN; Miller LL; Lannutti BJ; Furman RR; Jessen KA; Deaglio S
    Blood; 2021 Jun; 137(24):3365-3377. PubMed ID: 33512452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
    Zhang Q; Wang HY; Liu X; Nunez-Cruz S; Jillab M; Melnikov O; Nath K; Glickson J; Wasik MA
    J Immunol; 2019 Oct; 203(8):2043-2048. PubMed ID: 31534006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; Leeming A; McIntosh J; Huang S; Zhang R; Cai Q; Chen Z; Li Y; Che Y; Nie L; Karlsson I; Mårtensson L; Kovacek M; Teige I; Frendéus B; Wang M
    J Hematol Oncol; 2022 Apr; 15(1):42. PubMed ID: 35410313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
    Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
    Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
    Romancik JT; Gerber DG; Zhuang T; Cohen JB
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):557-565. PubMed ID: 35123927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.
    Munoz JL; Wang Y; Jain P; Wang M
    Curr Oncol Rep; 2022 Oct; 24(10):1299-1311. PubMed ID: 35596920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapies in mantle cell lymphoma.
    Hanel W; Epperla N
    J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
    Hudecek M; Lupo-Stanghellini MT; Kosasih PL; Sommermeyer D; Jensen MC; Rader C; Riddell SR
    Clin Cancer Res; 2013 Jun; 19(12):3153-64. PubMed ID: 23620405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.
    Jiang VC; Hao D; Jain P; Li Y; Cai Q; Yao Y; Nie L; Liu Y; Jin J; Wang W; Lee HH; Che Y; Dai E; Han G; Wang R; Rai K; Futreal A; Flowers C; Wang L; Wang M
    Mol Cancer; 2022 Sep; 21(1):185. PubMed ID: 36163179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.
    Deshpande A; Wang Y; Munoz J; Jain P
    Drugs Today (Barc); 2022 Jun; 58(6):283-298. PubMed ID: 35670706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
    Reagan PM; Friedberg JW
    Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.
    Wang ML; Barrientos JC; Furman RR; Mei M; Barr PM; Choi MY; de Vos S; Kallam A; Patel K; Kipps TJ; Rule S; Flanders K; Jessen KA; Ren H; Riebling PC; Graham P; King L; Thurston AW; Sun M; Schmidt EM; Lannutti BJ; Johnson DM; Miller LL; Spurgeon SE
    NEJM Evid; 2022 Jan; 1(1):EVIDoa2100001. PubMed ID: 38319241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors.
    Nayak RK; Gerber D; Zhang C; Cohen JB
    Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):861-865. PubMed ID: 37661513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
    Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
    Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
    Ruella M; Kenderian SS; Shestova O; Fraietta JA; Qayyum S; Zhang Q; Maus MV; Liu X; Nunez-Cruz S; Klichinsky M; Kawalekar OU; Milone M; Lacey SF; Mato A; Schuster SJ; Kalos M; June CH; Gill S; Wasik MA
    Clin Cancer Res; 2016 Jun; 22(11):2684-96. PubMed ID: 26819453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T-Cell therapy for the management of mantle cell lymphoma.
    Huang Z; Chavda VP; Bezbaruah R; Dhamne H; Yang DH; Zhao HB
    Mol Cancer; 2023 Mar; 22(1):67. PubMed ID: 37004047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions.
    Bond DA; Martin P; Maddocks KJ
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33799484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Directions for Mantle Cell Lymphoma in 2022.
    Kumar A; Eyre TA; Lewis KL; Thompson MC; Cheah CY
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35561299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.